Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy
Source: SeekingAlpha
2026-02-23 14:51:12 ET
Investment Overview
Vanda Pharmaceuticals Inc. ( VNDA ) stock is soaring today , in reaction to the company's after-hours announcement last Friday that :
that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a first line therapy for the acute treatment of manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults.
Read the full article on Seeking Alpha
For further details see:
Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy
Vanda Pharmaceuticals Inc.
NASDAQ: VNDA
VNDA Trading
5.02% G/L:
$8.265 Last:
655,359 Volume:
$7.73 Open:
VNDA Latest News
March 03, 2026 08:01:00 am
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
February 26, 2026 04:35:00 pm
Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
February 25, 2026 07:18:00 am
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
February 23, 2026 02:31:32 pm
Vanda Pharmaceuticals Stock Surges Following FDA Approval of New Psychiatric Drug
VNDA Stock Data
$442,042,792
53,186,967
3.95%
43
N/A
Biotechnology & Life Sciences
Healthcare
US
Washington
